Articles

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma

Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona
Grup d’Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Pathology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat
Institut Catalá d’Oncología, Hospital Duran I Reynals, L’Hospitalet de Llobregat
Institut Catalá d’Oncología, Hospital Duran I Reynals, L’Hospitalet de Llobregat
Pathology Department, IMIM, Hospital del Mar, Barcelona
Pathology Department, IMIM, Hospital del Mar, Barcelona
Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona
Department of Hematology, Hospital Clinic, Barcelona
Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona;Grup d’Oncogènesi i Antitumorals, lnstitut d’Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona
Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona;Grup d’Oncogènesi i Antitumorals, lnstitut d’Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona
Hematology Research Group, Health Research Institute La Fe, Valencia
Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona
Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona;Institucio Catalana de Recerca I Estudis Avançats (ICREA), CIBERONC, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona;Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona;Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Grup d’Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
Grup d’Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona;Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona;Department of Hematology, Hospital Clinic, Barcelona
Grup d’Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona
Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona;Pathology Department, IMIM, Hospital del Mar, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona
Division of Hemato-Oncology, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona;Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
Vol. 104 No. 4 (2019): April, 2019 https://doi.org/10.3324/haematol.2017.180505